Kaimakliotis, H. Z., Adra, N., Kelly, W. K., Trabulsi, E. J., Lauer, R. C., Picus, J., … Hoimes, C. J. (2020). Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): Interim results from the cisplatin (C)-ineligible cohort of GU14-188. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).

Kaimakliotis, Hristos Z., Nabil Adra, William Kevin Kelly, Edouard John Trabulsi, Richard C. Lauer, Joel Picus, Zachary L. Smith, et al. “Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): Interim results from the cisplatin (C)-ineligible cohort of GU14-188.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.

Kaimakliotis HZ, Adra N, Kelly WK, Trabulsi EJ, Lauer RC, Picus J, et al. Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): Interim results from the cisplatin (C)-ineligible cohort of GU14-188. In: JOURNAL OF CLINICAL ONCOLOGY. 2020.

Kaimakliotis, Hristos Z., et al. “Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): Interim results from the cisplatin (C)-ineligible cohort of GU14-188.” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 15, 2020.

Kaimakliotis HZ, Adra N, Kelly WK, Trabulsi EJ, Lauer RC, Picus J, Smith ZL, Walling R, Masterson TA, Calaway AC, Koch MO, Sonderman E, Fu P, Goolamier G, Eitman C, Ponsky LE, Hoimes CJ. Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): Interim results from the cisplatin (C)-ineligible cohort of GU14-188. JOURNAL OF CLINICAL ONCOLOGY. 2020.